Back HCV Policy & Advocacy

HCV Policy & Advocacy

War on Drugs Is Major Driver of Global Hepatitis C Epidemic

The so-called "war on drugs" plays a major role is sustaining hepatitis C epidemics worldwide, including in hard-hit Russia and Eastern Europe, according to the latest report from the Global Commission on Drug Policy. Drug prohibition drives drug users underground and blocks harm reduction efforts such as needle exchange programs. "The war on drugs is a war on common sense," said Commissioner Ruth Dreifuss.alt

Read more:

EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients

European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the EASL International Liver Congress (EASL 2013) in Amsterdam last week. However, clear differences in opinion emerged between patients and doctors regarding who should make decisions about acceptable levels of risk to patients during a symposium on compassionate use organized by the European Liver Patients Association.alt

Read more:

New Hepatitis C Helpline Offers Information and Referrals

On February 1, The Support Partnership for Hepatitis C (TSP) launched a new project to connect people living with hepatitis C to resources and services in their communities.alt

Read more:

EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics

Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.


Read more:

AASLD and Trust for America's Health Call for Action on Hepatitis B and C

Millions of Americans are living with chronic hepatitis B or C, but many do not know they are infected and are not receiving appropriate care, according to a new report issued by the American Association for the Study of Liver Diseases (AASLD) and the Trust for America's Health (TFAH). Over years or decades, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection can cause advanced liver disease -- including liver cirrhosis and hepatocellular carcinoma -- which is projected to be a growing public health concern in the coming years.

Read more: